Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Brent Pfeiffenberger, President and CEO of Century Therapeutics , Inc. (NASDAQ:IPSC), recently executed a transaction involving the sale of 2,235 shares of the company’s common stock. The shares were ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in ...

Eric Shaff; President, Chief Executive Officer, Director; Seres Therapeutics Inc Lisa von Moltke; Executive Vice President, Chief Medical Officer; Seres Therapeutics Inc Matthew Henn; Executive Vice ...

Our periodic round-up of financings in the biotech sector is led by an impressive nine-figure round for UK vaccines developer Vicebio, with GC Therapeutics, Genespire, and 858 Therapeutics also in ...

Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Lip-Bu Tan, who is set to take over as Intel’s chief executive next week, is a veteran of the semiconductor industry who has an even longer track record as a technology investor, particularly in ...

The company announced Wednesday that it has named longtime tech investor and semiconductor industry executive Lip-Bu Tan as chief executive, after former CEO Pat Gelsinger resigned in December.

As he steps into one of the highest-profile jobs on the planet, CEO of troubled, storied chipmaker Intel, his performance will be on full display. Tan, named Intel CEO on Wednesday, faces an ...